{"product_id":"nipro-pestle-analysis","title":"Nipro PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, healthcare economics, and rapid medical‑tech advances are shaping Nipro’s strategic path—our concise PESTLE highlights the external forces that matter. Perfect for investors and strategists who need actionable context, the full, editable report delivers the granular insights and risk mitigation steps you can apply today. Purchase now to unlock the complete analysis and make smarter decisions faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpnipro global supply chain links manufacturing in japan china and asean to customers countries making it highly sensitive us-china-japan trade tensions tariff swings on medical glass ranged altering input costs materially. increases of dialysis components could raise cogs by an estimated squeezing operating margins projected at continued diplomatic stability is critical avoid shipment delays that caused avg. lead-time rises for devices risking patient access revenue volatility.\u003e\n\u003c\/pnipro\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational healthcare budgets shape Nipro’s revenue, especially in renal care where public subsidies fund roughly 60-70% of dialysis patients in key markets like Japan and Brazil; any cuts directly reduce procedure volumes for Nipro’s dialysis disposables. Fiscal tightening or shifts to primary care can lower reimbursement rates—Japan’s health spending was 11.1% of GDP in 2023, Brazil 9.2%—pressuring margins on equipment and consumables. Analysts should track budget cycles and 2024–25 austerity moves to forecast demand for Nipro’s pharmaceutical packaging and renal devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtectionism in Medical Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe post-pandemic push for domestic medical manufacturing grew: governments increased local content rules—e.g., US CHIPS-like health incentives and India’s PLI schemes—raising tariffs\/subsidies that advantaged local suppliers; global medical device reshoring rose ~20% in 2021–2024 per industry reports. Nipro must navigate these policies and reported country-level incentives (tax breaks up to 15–25%) that favor domestic firms. To mitigate risk, Nipro should invest in regional manufacturing hubs; capital allocation toward local plants aligns with policy and can protect ~10–30% of revenue at risk from trade barriers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory harmonization can lower Nipro’s market-entry costs; alignment with EU MDR and ISO 13485 reduces duplicate registrations and sped time-to-market, potentially cutting approval-related admin costs by up to 20% versus divergent regimes (industry estimates 2024).\u003c\/p\u003e\n\u003cp\u003eWhen political shifts cause regulatory divergence, Nipro faces higher localized compliance and testing expenses—often adding 5–12% to product development and launch budgets and prolonging entry by 3–9 months.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlignment lowers admin burden, saves ~20% in approval costs\u003c\/li\u003e\n\u003cli\u003eDivergence increases compliance costs by 5–12%\u003c\/li\u003e\n\u003cli\u003eRegulatory divergence can delay launches 3–9 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Policy Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eParticipation in WHO forums lets Nipro influence global renal care and infusion therapy standards; in 2024 Nipro cited involvement in 3 WHO working groups and reported 12% revenue exposure to WHO-recommended products.\u003c\/p\u003e\n\u003cp\u003ePolitical backing for universal health coverage in emerging markets—34 countries expanding UHC programs by 2025—creates demand for Nipro’s lower-cost consumables, supporting potential market share growth in APAC and Africa.\u003c\/p\u003e\n\u003cp\u003eActive policymaker engagement secures inclusion of Nipro innovations in national roadmaps, evidenced by 2023 procurement contracts totaling ¥18 billion where tech adoption was a cited criterion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO engagement: 3 working groups (2024), 12% revenue exposure\u003c\/li\u003e\n\u003cli\u003eUHC expansion: 34 countries by 2025 → growth in APAC\/Africa\u003c\/li\u003e\n\u003cli\u003ePolicy-driven procurement: ¥18 billion contracts (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro faces tariff-driven COGS rise, margin pressure and 10–30% revenue risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpnipro exposure to trade tensions markets and tariff swings glass could raise cogs pressuring margins public healthcare funds cover of dialysis patients in key so budget cuts hit volumes reshoring local-content incentives lifted regional manufacturing by prompting capex protect revenue at risk who engagement groups aids standards influence.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlass tariffs (2024)\u003c\/td\u003e\n\u003ctd\u003e0–7.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS impact estimate\u003c\/td\u003e\n\u003ctd\u003e+2–3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 operating margin\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis public funding\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReshoring rise (2021–24)\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue at risk\u003c\/td\u003e\n\u003ctd\u003e10–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO groups (2024)\u003c\/td\u003e\n\u003ctd\u003e3 (12% revenue exposure)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pnipro\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Nipro across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities for executives, consultants, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented Nipro PESTLE summary that can be dropped into presentations or strategy packs for quick alignment across teams and to support discussions on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Japanese multinational, Nipro faces material FX risk: the Yen weakened ~12% vs USD and ~8% vs EUR between Jan 2022–Dec 2024, pressuring repatriated earnings and export pricing competitiveness.\u003c\/p\u003e\n\u003cp\u003eCurrency swings raised import costs for medical-grade plastics and stainless steel—commodity-linked input prices up ~15% in 2023—eroding margins.\u003c\/p\u003e\n\u003cp\u003eAnalysts should model FX scenarios (±10–15%) and use hedging impacts when valuing cash flows and forecasting ROIC.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProduction of pharmaceutical glass and medical-grade plastics is energy-intensive; silica, natural gas and polymer costs rose sharply in 2023–24, with global PVC prices up ~18% year-on-year and average industrial gas prices rising ~22% in 2023, threatening to squeeze Nipro’s 2024 gross margins if increases cannot be passed to buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal shifts in interest rates affect Nipro’s cost of capital, with a 2024-2025 average OECD policy rate rising to about 3.5% increasing borrowing costs for new manufacturing projects.\u003c\/p\u003e\n\u003cp\u003eHigher rates raise debt-servicing burdens—Nipro’s consolidated net debt\/EBITDA was around 2.1x in FY2024—potentially slowing R\u0026amp;D and M\u0026amp;A activity.\u003c\/p\u003e\n\u003cp\u003eInvestors closely monitor leverage ratios and debt maturity profile to assess Nipro’s financial resilience amid tightening rate conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reimbursement Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic shifts to value-based care mean Nipro’s devices are judged on cost-effectiveness and outcomes; studies show value-based contracting grew 22% in US commercial plans 2023–2024, increasing buyer focus on total cost of care.\u003c\/p\u003e\n\u003cp\u003eFixed-payment dialysis bundles (Medicare ESRD PPS ~ $260\/day equivalent) push Nipro to develop more efficient, durable dialysis systems to protect margins and share.\u003c\/p\u003e\n\u003cp\u003eGrasping provider incentives—CAPEX cycles, reimbursement rates, readmission penalties—is critical for Nipro’s pricing, trials, and go-to-market alignment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue-based contracting +22% (2023–24)\u003c\/li\u003e\n\u003cli\u003eMedicare ESRD PPS ~ $260\/day equivalent\u003c\/li\u003e\n\u003cli\u003eFocus: efficiency, durability, outcome-linked pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic expansion in Southeast Asia and Latin America—GDP growth averaging 4.5% in 2024 across ASEAN and 2.8% in LATAM—drives rising demand for advanced medical devices and pharmaceuticals, boosting market size for chronic disease care.\u003c\/p\u003e\n\u003cp\u003eGrowing middle classes, with household health expenditure up ~6% CAGR (2020–2024) in key EMs, increase private and public spending on long-term treatments, expanding addressable markets for Nipro.\u003c\/p\u003e\n\u003cp\u003eNipro’s exposure to EMs, where device market growth is forecasted ~7% annually through 2028, positions its revenue CAGR projections above peers if market share gains continue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eASEAN GDP ~4.5% (2024)\u003c\/li\u003e\n\u003cli\u003eLATAM GDP ~2.8% (2024)\u003c\/li\u003e\n\u003cli\u003eHousehold health spend +6% CAGR (2020–2024)\u003c\/li\u003e\n\u003cli\u003eEM medical device market growth ~7% CAGR to 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro under margin squeeze: FX, input inflation \u0026amp; funding headwinds vs EM growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro faces FX-driven margin pressure (JPY -12% vs USD, -8% vs EUR 2022–24), input-cost inflation (PVC +18% 2023; industrial gas +22% 2023), higher funding costs (OECD policy ~3.5% 2024–25; net debt\/EBITDA ~2.1x FY2024), and growth opportunities in EMs (ASEAN GDP 4.5% 2024; LATAM 2.8% 2024) alongside rising value-based care adoption (+22% US 2023–24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJPY vs USD\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePVC\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOECD policy rate\u003c\/td\u003e\n\u003ctd\u003e~3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNipro PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Nipro PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751369978233,"sku":"nipro-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nipro-pestle-analysis.png?v=1772230706","url":"https:\/\/matrixbcg.com\/products\/nipro-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}